Monograph Details
|
|
Urogenital System
> Benign prostatic hyperplasia/urinary retention
|
|
PROSCAR |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Type II 5α-reductase inhibitor. |
| Generic Name |
|
Finasteride 5mg; tabs. |
| Indications |
|
BPH, to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery. To reduce risk of symptomatic progression of BPH, with doxazosin. |
| Children |
|
Not applicable. |
| Adults |
|
5mg once daily. Reevaluate at 6 months, then periodically. |
| Contraindications |
|
Not for use in children or women. Pregnant women and those of childbearing potential should avoid handling crushed or broken tablets. |
| Precautions |
|
Hepatic dysfunction. Monitor prostate specific antigen (PSA) values; double PSA levels for comparison with normal ranges. Monitor for prostate cancer, obstructive uropathy. Exclude prostate cancer. |
| Adverse Reactions |
|
Impotence, decreased libido or ejaculate volume, mastodynia. |
| How Supplied |
|
Tabs—30, 100, 1000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
